There's no backlog. Specials does 5-7 patients a year and has for the last 3. Unless you think the company's capacity with all shareholders have pumped into LP's private Advent can only produce vaccines for 5-7 patients. LP said Cognate could meet all demand back in 2017. Why'd she sell it then?
Nobody wants to drop $200K for an unapproved treatment that couldn't prove efficacy in a 10 year long P3. They probably want the placebo since the mOS was better than the treatment in the P3.
News 
Market Data 
Discover 
